Human Genome Sciences
Print
ABOUT HGS

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

We are poised for the market with a clinical pipeline that includes three novel products in late-stage development: Albuferon® in Phase 3 trials for hepatitis C, LymphoStat-B® in Phase 3 trials for systemic lupus, and ABthrax™ in late-stage development for inhalation anthrax.

Both Albuferon and LymphoStat-B have the therapeutic potential to change and save lives and the commercial potential to become blockbusters in the marketplace. Each is being co-developed and commercialized in collaboration with a world leader in the pharmaceutical industry – Novartis for Albuferon and GlaxoSmithKline (GSK) for LymphoStat-B.

ABthrax is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalation anthrax. The pivotal efficacy studies have demonstrated a dramatic and significant survival benefit, and we are manufacturing on schedule to begin delivery of ABthrax to the Strategic National Stockpile by fall 2008.

Right behind these three late-stage products is a high-potential mid-stage pipeline led by our TRAIL receptor antibodies for cancer – and including a number of products to which HGS has substantial financial rights in the GSK pipeline.

Our manufacturing capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows us to focus on advancing our lead products toward commercialization as rapidly as possible, while at the same time investing in our early- and mid-stage pipeline. We are committed to achieving and sustaining growth well into the future.